SB 258585 hydrochloride
Potent and selective 5-HT6 receptor antagonist (pKi = 8.6); displays > 160-fold selectivity over other 5-HT receptor subtypes.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 523.82. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||3.82 mL||19.09 mL||38.18 mL|
|2.5 mM||0.76 mL||3.82 mL||7.64 mL|
|5 mM||0.38 mL||1.91 mL||3.82 mL|
|25 mM||0.08 mL||0.38 mL||0.76 mL|
References are publications that support the biological activity of the product.
Bromidge et al (1999) 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J.Med.Chem. 42 202 PMID: 9925723
East et al (2002) 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 45 191 PMID: 12112397
Hirst et al (2000) Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue. Br.J.Pharmacol. 130 1597 PMID: 10928963
If you know of a relevant reference for SB 258585 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: SB 258585 hydrochloride, SB 258585 hydrochloride supplier, Potent, selective, 5-HT6, antagonists, Serotonin, Receptors, 5-Hydroxytryptamine, SB258585, hydrochloride, GlaxoSmithKline, GSK, 1961, Tocris Bioscience
3 Citations for SB 258585 hydrochloride
Citations are publications that use Tocris products. Selected citations for SB 258585 hydrochloride include:
Sun et al (2018) Activation and blockade of basolateral amygdala 5-HT6 receptor produce anxiolytic-like behaviors in an experimental model of Parkinson's disease. Neuropharmacology 137 275 PMID: 29778944
Hampson et al (2007) Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs. Diabetologia 50 1743 PMID: 17579833
Yun et al (2016) Peripheral serotonin-mediated system suppresses bone development and regeneration via serotonin 6 G-protein-coupled receptor. Scientific Reports 6 30985 PMID: 27581523
Do you know of a great paper that uses SB 258585 hydrochloride from Tocris? Please let us know.
Reviews for SB 258585 hydrochloride
There are currently no reviews for this product. Be the first to review SB 258585 hydrochloride and earn rewards!
Have you used SB 258585 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.